Educational disparities in antipsychotic drug use among older people with and without dementia in Sweden

Acta Psychiatrica Scandinavica

Volumn 132, Issue 1, 2015, Pages 20-28

  Wastesson, Jonas W ^a   Ringback Weitoft G ^b   Johnell, K ^a  

^a STOCKHOLM UNIVERSITY   (Sweden)

^b NATIONAL BOARD OF HEALTH AND WELFARE   (Sweden)

Author keywords

Aged; Antipsychotic agents; Dementia; Healthcare disparities; Socioeconomic factors

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CHLORPROTHIXENE; CHOLINESTERASE INHIBITOR; CLOZAPINE; DIXYRAZINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; NEUROLEPTIC AGENT; NOOTROPIC AGENT; OLANZAPINE; PERPHENAZINE; PROCHLORPERAZINE; RISPERIDONE; ZIPRASIDONE; ZUCLOPENTHIXOL;

AGED; ARTICLE; BEHAVIOR DISORDER; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DRUG USE; EDUCATIONAL STATUS; ELDERLY CARE; FEMALE; HEALTH CARE DISPARITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PATIENT EDUCATION; PRIORITY JOURNAL; SOCIAL STATUS; SWEDEN; VERY ELDERLY; ATTITUDE TO HEALTH; DRUG UTILIZATION; HEALTH CARE DELIVERY; REGISTER; STATISTICS AND NUMERICAL DATA;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; ATTITUDE TO HEALTH; DEMENTIA; DRUG UTILIZATION; EDUCATIONAL STATUS; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; REGISTRIES; SWEDEN;

EID: 84931572375     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12378     Document Type: Article

References (44)

1. Finkel SI, e Silva JC, Cohen GD, Miller S, Sartorius N. Behavioral and psychological symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Am J Geriatr Psychiatry 1998;6:97-100.
2. Hope T, Keene J, Fairburn CG, Jacoby R, McShane R. Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease. A longitudinal study. Br J Psychiatry 1999;174:39-44.
3. Paulsen JS, Salmon D, Thal L et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54:1965-1971.
4. Giron MST, Forsell Y, Bernsten C, Thorslund M, Winblad B, Fastbom J. Psychotropic drug use in elderly people with and without dementia. Int J Geriatr Psychiatry 2001;16:900-906.
5. Puyat JH, Law MR, Wong ST, Sutherland JM, Morgan SG. The essential and potentially inappropriate use of antipsychotics across income groups: an analysis of linked administrative data. Can J Psychiatry 2012;57:488-495.
6. Lövheim H, Karlsson S, Gustafson Y. The use of central nervous system drugs and analgesics among very old people with and without dementia. Pharmacoepidemiol Drug Saf 2008;17:912-918.
7. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
8. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia. JAMA 2005;294:1934-1943.
9. Schneider LS, Tariot PN, Dagerman KS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-1538.
10. Ballard C, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease: review. Cochrane Database Syst Rev 2006;1. doi: 10.1002/14651858.CD003476.pub2.
11. Socialstyrelsen (National Board of Health and Welfare). Nationella riktlinjer för vård och omsorg vid demenssjukdom [National guidelines for treatment and care of dementia disorder]. Edita Västra Aros: Västerås, 2010 (in Swedish).
12. Läkemedelsverket (Swedish Medical Products Agency). Läkemedelsbehandling och bemötande vid Beteendemässiga och Psykiska Symtom vid Demenssjukdom - "BPSD" [Treatment of behavioural and psychological symptoms of dementia - BPSD] (in Swedish). Information från Läkemedelsverket; 5:2008.
13. Turnheim K. When drug therapy gets old: pharmacokinetics and pharmacodynamics in the elderly. Exp Gerontol 2003;38:843-854.
14. Lee PE, Gill SS, Freedman M, Bronskill SE, Hillmer MP, Rochon PA. Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. Br Med J 2004;329:75.
15. Leucht S, Cipriani A, Spineli L et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-962.
16. Aro S, Aro H, Salinto M, Keskimäki I. Educational level and hospital use in mental disorders A population-based study. Acta Psychiatr Scand 1995;91:305-312.
17. Sharp ES, Gatz M. The relationship between education and dementia an updated systematic review. Alzheimer Dis Assoc Disord 2011;25:289.
18. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Geriatr Psychiatry 2005;162:2022-2030.
19. van der Linde RM, Stephan B, Savva GM, Dening T, Brayne C. Systematic reviews on behavioural and psychological symptoms in the older or demented population. Alzheimers Res Ther 2012;4:28.
20. van der Linde R, Stephan BC, Matthews FE, Brayne C, Savva GM. Behavioural and psychological symptoms in the older population without dementia-relationship with socio-demographics, health and cognition. BMC Geriatr 2010;10:87.
21. Haibo X, Shifu X, Pin NT et al. Prevalence and severity of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Chinese: findings from the Shanghai three districts study. Aging Ment Health 2013;17:748-752.
22. Lesén E, Andersson K, Petzold M, Carlsten A. Socioeconomic determinants of psychotropic drug utilisation among elderly: a national population-based cross-sectional study. BMC Public Health 2010;10:118. doi: 10.1186/471-2458-10-118.
23. Johnell K, Ringbäck Weitoft G, Fastbom J. Education and use of dementia drugs: a register-based study of over 600, 000 older people. Dement Geriatr Cogn Disord 2008;25:54-59.
24. Moustgaard H, Joutsenniemi K, Martikainen P. Does hospital admission risk for depression vary across social groups? A population-based register study of 231, 629 middle-aged Finns. Soc Psychiatry Psychiatr Epidemiol 2014;49:15-25.
25. Wastesson J, Fastbom J, Ringbäck Weitoft G, Fors S, Johnell K. Socioeconomic inequalities in access to specialised psychotropic prescribing among older Swedes: a register based study. Eur J Public Health 2014;24:991-6.
26. Wettermark B, Hammar N, MichaelFored C et al. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-735.
27. Ludvigsson JF, Andersson E, Ekbom A et al. External review and validation of the Swedish national inpatient register. BMC Public Health 2011;11:450.
28. Statistics Sweden. Utbildningsregistret [The Swedish Register of Education] http://www.scb.se/statistik/UF/UF0506/SUN2000English%20version.doc. [Accessed 2013 03 02].
29. World Health Organization (WHO). ICD-10: international statistical classification of diseases and related health problems: tenth revision, 2nd edn. Geneva: WHO, 2004.
30. World Health Organization, Collaborating Centre for Drug Statistics Methodology, Oslo, Norway: http://www.whocc.no/ [Accessed 2013 04 07].
31. Calvó-Perxas L, de Eugenio RM, Marquez-Daniel F et al. Profile and variables related to antipsychotic consumption according to dementia subtypes. Int Psychogeriatr 2012;24:940-947.
32. Jin Y-P, Gatz M, Johansson B, Pedersen NL. Sensitivity and specificity of dementia coding in two Swedish disease registries. Neurology 2004;63:739-741.
33. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001;154:854-864.
34. Laitinen M-L, Bell JS, Lavikainen P, Lönnroos E, Sulkava R, Hartikainen S. Nationwide study of antipsychotic use among community-dwelling persons with Alzheimer's disease in Finland. Int Psychogeriatr 2011;23:1623-1631.
35. Johnell K, Religa D, Eriksdotter M. Differences in drug therapy between dementia disorders in the Swedish Dementia Registry: a nationwide study of over 7, 000 patients. Dement Geriatr Cogn Disord 2013;35:239-248.
36. Fereshtehnejad S-M, Johnell K, Eriksdotter M. Anti-dementia drugs and co-medication among patients with Alzheimer's disease. Drugs Aging 2014;31:215-224.
37. Kaufman J. Inequality in provision of medical care in Sweden: a case of social epidemiological hypochondria? J Epidemiol Community Health 2010;64:651-652.
38. Goddard M, Smith P. Equity of access to health care services: theory and evidence from the UK. Soc Sci Med 2001;53:1149-1162.
39. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010;121:4-10.
40. Haider SI, Johnell K, Ringbäck Weitoft G, Thorslund M, Fastbom J. Patient educational level and use of newly marketed drugs: a register-based study of over 600, 000 older people. Eur J Clin Pharmacol 2008;64:1215-1222.
41. Lövheim H, Sandman P-O, Karlsson S, Gustafson Y. Sex differences in the prevalence of behavioral and psychological symptoms of dementia. Int Psychogeriatr 2009;21:469-475.
42. Munk-Jørgensen P, Okkels N, Golberg D, Ruggeri M, Thornicroft G. Fifty years' development and future perspectives of psychiatric register research. Acta Psychiatr Scand 2014;130:87-98.
43. Tjia J. Potentially inappropriate use of antipsychotics in community-dwelling adults with dementia more common in those with low income. Evid Based Ment Health 2013;16:56.
44. Sköldunger A, Wimo A, Johnell K. Net costs of dementia in Sweden-an incidence based 10 year simulation study. Int J Geriatr Psychiatry 2012;27:1112-1117.